367 related articles for article (PubMed ID: 31787568)
1. Evaluation of posaconazole antifungal prophylaxis in reducing the incidence of invasive aspergillosis in patients with acute myeloid leukemia.
Le Clech L; Uguen M; Quinio D; Nevez G; Couturier MA; Ianotto JC; Berthou C; Guillerm G; Le Bars H; Payan C; Narbonne V; Baron R; Saliou P
Curr Res Transl Med; 2020 Jan; 68(1):23-28. PubMed ID: 31787568
[TBL] [Abstract][Full Text] [Related]
2. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters.
Oren I; Haddad N; Finkelstein R; Rowe JM
Am J Hematol; 2001 Apr; 66(4):257-62. PubMed ID: 11279636
[TBL] [Abstract][Full Text] [Related]
3. Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: A single-center, observational, case-control study in South Korea.
Yang E; Choi EJ; Park HS; Lee SO; Choi SH; Kim YS; Lee JH; Lee JH; Lee KH; Kim SH
Medicine (Baltimore); 2021 May; 100(20):e25448. PubMed ID: 34011022
[TBL] [Abstract][Full Text] [Related]
4. Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
Dahlén T; Kalin M; Cederlund K; Nordlander A; Björkholm M; Ljungman P; Blennow O
Eur J Haematol; 2016 Feb; 96(2):175-80. PubMed ID: 25880378
[TBL] [Abstract][Full Text] [Related]
5. Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.
Girmenia C; Frustaci AM; Gentile G; Minotti C; Cartoni C; Capria S; Trisolini SM; Matturro A; Loglisci G; Latagliata R; Breccia M; Meloni G; Alimena G; Foà R; Micozzi A
Haematologica; 2012 Apr; 97(4):560-7. PubMed ID: 22102706
[TBL] [Abstract][Full Text] [Related]
6. Itraconazole vs. posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia undergoing intensive chemotherapy: A retrospective study.
Copley MS; Waldron M; Athans V; Welch SC; Brizendine KD; Cober E; Siebenaller C
Int J Antimicrob Agents; 2020 Mar; 55(3):105886. PubMed ID: 31926286
[TBL] [Abstract][Full Text] [Related]
7. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
[TBL] [Abstract][Full Text] [Related]
8. [Breakthrough of invasive fungal disease with posaconazole as primary prophylaxis after induction chemotherapy for acute myeloid leukemia].
Pei RZ; Lu Y; Zhang PS; Liu XH; Chen D; Du XH; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Tang SH
Zhonghua Nei Ke Za Zhi; 2020 Mar; 59(3):213-217. PubMed ID: 32146748
[No Abstract] [Full Text] [Related]
9. Airborne fungal spores and invasive aspergillosis in hematologic units in a tertiary hospital during construction: a prospective cohort study.
Park JH; Ryu SH; Lee JY; Kim HJ; Kwak SH; Jung J; Lee J; Sung H; Kim SH
Antimicrob Resist Infect Control; 2019; 8():88. PubMed ID: 31161035
[TBL] [Abstract][Full Text] [Related]
10. 'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study.
Del Principe MI; Dragonetti G; Verga L; Candoni A; Marchesi F; Cattaneo C; Delia M; Potenza L; Farina F; Ballanti S; Decembrino N; Castagnola C; Nadali G; Fanci R; Orciulo E; Veggia B; Offidani M; Melillo L; Manetta S; Tumbarello M; Venditti A; Busca A; Aversa F; Pagano L;
J Antimicrob Chemother; 2019 Apr; 74(4):1062-1068. PubMed ID: 30649413
[TBL] [Abstract][Full Text] [Related]
11. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.
Phillips K; Cirrone F; Ahuja T; Siegfried J; Papadopoulos J
J Oncol Pharm Pract; 2019 Mar; 25(2):398-403. PubMed ID: 30319061
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole.
Michallet M; Sobh M; Morisset S; Kraghel S; Nicolini FE; Thomas X; Bienvenu AL; Picot S; Nicolle MC; Vanhems P
Med Mycol; 2011 Oct; 49(7):681-7. PubMed ID: 21314250
[TBL] [Abstract][Full Text] [Related]
13. A Quasi-Experimental Study Analyzing the Effectiveness of Portable High-Efficiency Particulate Absorption Filters in Preventing Infections in Hematology Patients during Construction.
Özen M; Yılmaz G; Coşkun B; Topçuoğlu P; Öztürk B; Gündüz M; Atilla E; Arslan Ö; Özcan M; Demirer T; İlhan O; Konuk N; Balık İ; Gürman G; Akan H
Turk J Haematol; 2016 Mar; 33(1):41-7. PubMed ID: 26376622
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
[TBL] [Abstract][Full Text] [Related]
15. Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
Pomares H; Arnan M; Sánchez-Ortega I; Sureda A; Duarte RF
Mycoses; 2016 Aug; 59(8):516-9. PubMed ID: 27027972
[TBL] [Abstract][Full Text] [Related]
16. Antifungal prophylaxis with fluconazole in allogeneic stem cell transplantation recipients who had prior invasive aspergillosis with subsequent complete resolution by computed tomography.
Akahoshi Y; Kimura SI; Gomyo A; Hayakawa J; Tamaki M; Harada N; Kusuda M; Kameda K; Ugai T; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Terasako-Saito K; Kikuchi M; Nakasone H; Kako S; Kanda Y
Infect Dis (Lond); 2018 Apr; 50(4):280-288. PubMed ID: 29087731
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of interventions for prevention of invasive aspergillosis among leukemia patients during hospital construction activities.
Combariza JF; Toro LF; Orozco JJ; Arango M
Eur J Haematol; 2018 Feb; 100(2):140-146. PubMed ID: 29105850
[TBL] [Abstract][Full Text] [Related]
18. Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial.
Fisher BT; Zaoutis T; Dvorak CC; Nieder M; Zerr D; Wingard JR; Callahan C; Villaluna D; Chen L; Dang H; Esbenshade AJ; Alexander S; Wiley JM; Sung L
JAMA; 2019 Nov; 322(17):1673-1681. PubMed ID: 31688884
[TBL] [Abstract][Full Text] [Related]
19. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.
Vehreschild JJ; Rüping MJ; Wisplinghoff H; Farowski F; Steinbach A; Sims R; Stollorz A; Kreuzer KA; Hallek M; Bangard C; Cornely OA
J Antimicrob Chemother; 2010 Jul; 65(7):1466-71. PubMed ID: 20410061
[TBL] [Abstract][Full Text] [Related]
20. Is Posaconazole Really Effective in Adolescent patients as a Prophylactic Agent: Experience of a Tertiary Care Center.
Arikan K; Aytac S; Büyükcam A; Cengiz AB; Cetinkaya FD; Cetin M; Ozsurekci Y; Ceyhan M; Kara A
J Pediatr Hematol Oncol; 2021 Jul; 43(5):e613-e618. PubMed ID: 33560081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
